Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

Pfizer to present data on hematology portfolio at ASH Annual Meeting

Pfizer said today that new data on investigational compounds in its hematology portfolio will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, December 4-7.

1 Dec 2010

Rush University enrolls first U.S. patient in international clinical trial for melanoma

Rush University Medical Center has just enrolled the first U.S. patient in an international clinical trial testing a novel drug to treat certain kinds of melanoma, a deadly skin cancer that in its advanced stages currently has few effective treatments.

1 Dec 2010

ARIAD to present clinical data on ponatinib for CML at ASH Annual Meeting

ARIAD Pharmaceuticals, Inc. today announced that updated clinical data from a fully enrolled Phase 1 trial of its investigational, pan-BCR-ABL inhibitor, ponatinib, will be presented at the 52nd Annual Meeting of the American Society of Hematology being held in Orlando, Florida, December 4-7, 2010.

30 Nov 2010

Overexpression of microRNA 125b can cause leukemia: Research

Whitehead Institute researchers have shown in mouse models that overexpression of the microRNA 125b (miR-125b) can independently cause leukemia and accelerate the disease's progression. Their results are published in this week's online edition of the Proceedings of the National Academy of Sciences (PNAS).

30 Nov 2010

Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting

Calistoga Pharmaceuticals, Inc., the leader in the development of delta-isoform-selective phosphatidylinositol 3-kinase (PI3K-delta) inhibitors for the treatment of cancer and inflammatory diseases, today announced the upcoming presentation of clinical and preclinical results supporting the clinical benefit of CAL-101, an oral, PI3K-delta inhibitor, in the treatment of patients with hematologic malignancies.

30 Nov 2010

Hana Biosciences to present Marqibo data for acute lymphoblastic leukemia at ASH Annual Meeting

Hana Biosciences, a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that data regarding Marqibo for treatment of adults with relapsed/refractory acute lymphoblastic leukemia (ALL) will be the subject of two presentations at the 2010 Annual Meeting and Exposition of the American Society of Hematology (ASH) being held in Orlando, Florida from December 4-7, 2010.

30 Nov 2010

JAK3 pathway highlighted as leukemia target

An intriguing study published in Expert Review of Anticancer Therapy has revealed that the signaling protein JAK3 represents a viable target in the treatment of a broad range of B-lineage cancers, including acute lymphoblastic leukemia (ALL).

28 Nov 2010

Elbit Imaging closes transaction with Enter

Elbit Imaging Ltd. announced today that, further to its announcement dated September 13, 2010, it has successfully closed the transaction with Enter Holdings 1 Ltd. and Enter's controlling shareholders.

25 Nov 2010

Collective efforts in transplantation reduces risk of treatment-related complications in blood cancer

A decade of refinements in marrow and stem cell transplantation to treat blood cancers significantly reduced the risk of treatment-related complications and death, according to an institutional self-analysis of transplant-patient outcomes conducted at Fred Hutchinson Cancer Research Center.

25 Nov 2010

Cord Blood America shares web site post on Thanksgiving Day

On this day before Thanksgiving, a day when our entire nation gives thanks for its blessing, Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, would like to share with its investors a post from its web site by Dr. Geoffrey O'Neill, CBAI Vice President, Operations.

24 Nov 2010

Researchers identify trigger mechanism for quality control checkpoint in cell division process

Researchers from Huntsman Cancer Institute (HCI) at the University of Utah report that they have identified a previously undiscovered trigger mechanism for a quality control checkpoint at the very end of the cell division process in a paper to be published in the November 29 issue of The Journal of Cell Biology and online today.

23 Nov 2010

$S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies$

S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies

S*BIO Pte Ltd today announced that a fourth novel, potential best-in-class compound discovered and developed by S*BIO has entered a Phase 1 clinical trial. The initiation of the study for S*BIO's oral multi-kinase inhibitor, SB1317 or TG02, in patients with advanced/refractory hematologic malignancies has triggered a payment from S*BIO's development and commercialization partner for the program, Tragara Pharmaceuticals.

22 Nov 2010

Researchers reconstitute first step of break repair in cancerous cells

What prompts normal cells to transform themselves into cancerous cells. Researchers from Texas institutions, including the UT Health Science Center San Antonio, have identified factors in the very first step of the process and reconstituted this first step in the test tube. The latter accomplishment was reported Sunday [Nov. 21] in the top-tier journal Nature Structural & Molecular Biology.

22 Nov 2010

Lotsa Helping Hands' new feature connects community members to healthcare nonprofit organizations

Lotsa Helping Hands, the leading provider of a web-based caregiving coordination service, today announces a new feature that connects its community members to trusted resources from many of the nation's leading healthcare nonprofit organizations.

20 Nov 2010

Dollar General joins St. Jude Children's Hospital for Thanks and Giving campaign

This holiday season, Dollar General again joins St. Jude Children's Research Hospital for the Thanks and Giving campaign by asking customers to "give thanks for the healthy kids in your life, and give to those who are not."

20 Nov 2010

Cyclacel to present results of sapacitabine Phase 2 trial for MDS at ASH Meeting

Cyclacel Pharmaceuticals, Inc. announced today that updated Phase 2 clinical trial results of sapacitabine for the treatment of myelodysplastic syndromes (MDS) will be presented at a poster presentation during the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, on Saturday, December 4, 2010.

19 Nov 2010

Personalised medicine could help develop effective treatments for serious diseases

Personalised medicine is a field that holds a lot of promise as a provider of practices and technology that could help develop more effective treatments for serious diseases such as cancer. Personalised medicine involves tailoring treatment according to the genetic profile and molecular makeup of each patient.

19 Nov 2010

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

A new drug that targets proteins responsible for helping cancer cells to repair damage to their DNA has shown promising anti-tumour activity in its first trial in humans.

18 Nov 2010

UC Berkeley receives $16.5 million to support three research centers to examine children's health

Researchers at the University of California, Berkeley's School of Public Health are getting $16.5 million to support three research centers as part of a federal initiative to examine the environmental factors influencing children's health.

18 Nov 2010

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

Merck announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee has advised that the data presented support an indication for GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] for the prevention of anal cancer and anal intraepithelial neoplasia (AIN) in both males and females 9 through 26 years of age.

18 Nov 2010

Leukemia News and Research

Further Reading

Pfizer to present data on hematology portfolio at ASH Annual Meeting

Rush University enrolls first U.S. patient in international clinical trial for melanoma

ARIAD to present clinical data on ponatinib for CML at ASH Annual Meeting

Overexpression of microRNA 125b can cause leukemia: Research

Calistoga to feature data on CAL-101 inhibitor for hematologic malignancies at ASH Annual Meeting

Hana Biosciences to present Marqibo data for acute lymphoblastic leukemia at ASH Annual Meeting

JAK3 pathway highlighted as leukemia target

Elbit Imaging closes transaction with Enter

Collective efforts in transplantation reduces risk of treatment-related complications in blood cancer

Cord Blood America shares web site post on Thanksgiving Day

Researchers identify trigger mechanism for quality control checkpoint in cell division process

S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies

Researchers reconstitute first step of break repair in cancerous cells

Lotsa Helping Hands' new feature connects community members to healthcare nonprofit organizations

Dollar General joins St. Jude Children's Hospital for Thanks and Giving campaign

Cyclacel to present results of sapacitabine Phase 2 trial for MDS at ASH Meeting

Personalised medicine could help develop effective treatments for serious diseases

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

UC Berkeley receives $16.5 million to support three research centers to examine children's health

Merck announces FDA Advisory Committee approval of GARDASIL for anal cancer and AIN treatment

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News